Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Breast Cancer Clinical Trial

Official title:

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00185809
• Other study ID #: BRSMTS0002
• Secondary ID: 75632BRSMTS0002N
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: July 16, 2010
• Start date: November 2000
• Est. completion date: August 2008

Study information

• Verified date: July 2010
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to examine breast cancers that express the protein (NIS) that may be found in malignant breast tissues and to evaluate proteins found in blood and their relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive iodine entering breast cancer cells, how long your cancer retains the agent as well as how much is taken up by other organs, particularly the thyroid gland.

Description:

To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide (131I).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 25
• Est. completion date: August 2008
• Est. primary completion date: August 2008
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:- Only women diagnosed with breast cancer

• 18 years of age or older

• From whom informed consent can be obtained

• Patient is able to provide a fluid (e.g. cyst fluid)

• Patient with blood test that shows protein may allow iodide to accumulate in breast tissue

• Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours

Exclusion Criteria:- Males

• Children

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	Susan G. Komen Breast Cancer Foundation

Country where clinical trial is conducted

United States,